Bristol-Myers Squibb acquired Turning Point Therapeutics for USD 4.1 billion. This acquisition gave Bristol-Myers Squibb access to Turning Point's pipeline of precision oncology drugs, including repotrectinib, which was approved by the FDA in 2021 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with ROS1 fusion.
Bristol-Myers Squibb merged with Celgene for USD 74 billion. This merger created one of the largest pharmaceutical companies in the world, with a focus on oncology, hematology, and cardiovascular disease.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5315
Published Date: Oct 13, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare is the major factor driving the market growth.
The market size of abrikossoff tumor treatment anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market are Novartis International AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Amgen Inc., Pfizer Inc., and others.
The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.